Scottish research identifies how chromosomal loop signatures could identify poor drug response in arthritis

Chromosomal loop signatures found in blood samples obtained in early rheumatoid arthritis could identify patients that will not respond adequately to ‘anchor’ treatment drug methotrexate.‌‌

New University of Glasgow research, published in the Journal of Translational Medicine, investigated whether differences in genomic architecture, as defined by a chromosome conformation signature (CCS) in blood taken pre-treatment from people with early rheumatoid arthritis, could assist in identifying the likelihood of a response to the first line disease-modifying anti-rheumatic drug (DMARD) methotrexate (MTX). The study successfully showed that a CCS found in the blood samples obtained in pre-treatment early rheumatoid arthritis could identify patients that will not respond adequately to MTX with a high degree of accuracy.

To read the full article, click here.